Download full-text PDF

Source
http://dx.doi.org/10.4038/cmj.v60i2.8159DOI Listing

Publication Analysis

Top Keywords

allogeneic bone
4
bone marrow
4
marrow transplant
4
transplant child
4
child thalassaemia
4
allogeneic
1
marrow
1
transplant
1
child
1
thalassaemia
1

Similar Publications

Myeloproliferative neoplasm-associated myelofibrosis is a clonal stem cell process characterized by pronounced bone marrow fibrosis associated with extramedullary hematopoiesis and splenomegaly. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents the only curative treatment leading to bone marrow fibrosis regression. Here we provide an in-depth skeletal characterization of myelofibrosis patients before and after allo-HSCT utilizing clinical high-resolution imaging, laboratory analyses, and bone biopsy studies.

View Article and Find Full Text PDF

Acute myeloid leukemia (AML) can be presented with extramedullary manifestations, more frequently involving skin and rarely other sites, such as the urinary tract. We report the case of a 37-year-old male patient with a history of testicular cancer who presented to the emergency department with cytopenias and hematuria. Bone marrow analysis diagnosed AML (French-American-British(FAB) classificationM4 subtype, karyotype showing inv16).

View Article and Find Full Text PDF

Background And Objectives: The immature platelet fraction (IPF) count is a parameter that quantifies young and reticulated platelets in peripheral blood, which reflects platelet production in the bone marrow. It has been used as a predictive model for bone marrow recovery in patients with acute leukemia after high-intensity chemotherapy and/or stem cell transplantation. This study aimed to evaluate IPF as a predictor of hematologic recovery in these patients.

View Article and Find Full Text PDF

Transfusion of blood products is a common lifesaving medical procedure in clinical practice. However, it poses the risk of potential adverse reactions for the recipient. Transfusion-associated graft-versus-host-disease (TA-GVHD) is a rare adverse event, fatal in >90% of cases.

View Article and Find Full Text PDF

A review on disease modifying pharmacologic therapies for sickle cell disease.

Ann Hematol

January 2025

Department of Internal Medicine, Section of Hematology/Oncology, University of Missouri-Kansas City, Kansas City, MO, 64108, USA.

Sickle cell disease (SCD) is an inherited hematologic disease caused by sickle hemoglobin as the predominant RBC hemoglobin or by sickle hemoglobin in combination with other abnormal β-hemoglobin variants like HbC, HbD and others. Sickling of erythrocytes under deoxygenated conditions is the basis of inflammatory and thrombotic cascades which result in multiple serious complications, leading to early morbidity and mortality. While HLA-matched allogeneic bone marrow transplantation is potentially curative, it has considerable limitations due to potential severe toxicities.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!